Research Evidence / Overview of Studies for Testosteron Depot EIFELFANGO
This overview summarizes the research base for Testosterone Enanthate, the active ingredient in this medicine. The text describes what types of studies have been conducted, what outcomes were measured, and where scientific data remain limited.
Evidence for Hormone Replacement in Adult Men with Hypogonadism
Research exploring the effects of testosterone replacement in adult men with confirmed low testosterone levels (hypogonadism) primarily relies on Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Studies were conducted during periods of increased symptom activity, and research examined how various outcomes related to systemic or functional imbalance changed over time.
Researchers typically studied men with classic hypogonadism and older men experiencing age-related decline. The main focus of research was on outcomes related to physical discomfort, such as changes in body composition (fat mass and lean muscle mass), bone mineral density, and measurements of patient-reported outcomes describing perceived discomfort like low libido and energy levels.
Studies reported how symptoms evolved in the observed populations. Findings describe patterns observed in the studies, and data show patterns related to lean body mass and fat mass over defined time intervals. Studies monitored changes in sexual function scores across various trials. However, the findings related to certain biochemical markers, such as blood lipid levels, were mixed and varied across different study reports.
Studies Examining Delayed Puberty in Adolescent Boys
The evidence base for using this medicine in adolescent boys with delayed puberty consists mainly of small, controlled clinical studies and case reports. Research has explored treatment applied in studies examining short-term or episodic symptom patterns related to growth and development.
These studies monitored parameters related to growth and maturation. Outcomes that were measured included the linear growth rate, the progression of secondary sexual characteristics (physical signs of puberty), and the advancement of bone age. The findings help contextualize how patients reported their experience during these short treatment courses, describing patterns observed in the studies related to pubertal onset and linear growth.
Evidence is limited for long-term physiological outcomes in this group. Subgroup findings are uncertain regarding the final measured adult height. There is limited information for long-term outcomes regarding the psychological and physical safety and efficacy after the short treatment period has ended, and clinical regimens may be informed by expert opinion rather than high-level RCTs.
Evidence from Specialized and Historical Use in Metastatic Breast Cancer
Research related to the use of testosterone in women with advanced metastatic breast cancer is primarily derived from historical clinical reports and documentation. This specialized use was studied for conditions associated with acute or disruptive episodes of advanced cancer.
Studies monitored oncologic response and described how patterns of tumor volume changed in treated women who were typically postmenopausal. Evidence included findings from studies that tracked this therapy's use for this specialized indication. Due to the historical context of use and the doses sometimes used in these reports, the evidence is considered limited.
Comparative evidence is lacking between this use and the treatments that have emerged from modern oncology research. This indication is highly specialized, and the existing data provide limited insight into how this therapy compares to contemporary systemic cancer treatments.
Long-Term Data and Durability of Effect
Most of the high-quality research on this medication involves follow-up durations that were limited to the short-term (under one year) or intermediate-term (up to three years) in the context of the primary indication.
Research highlights changes measured during the study period, but long-term effects are not fully established. Observational settings evaluating daily-life functioning through registry studies have provided some longer-duration data. However, evidence quality varies across studies, and study results reflect the specific conditions under which they were conducted, providing context but not individual predictions about the durability of response or the long-term maintenance of changes.
Evidence in Key Subgroups and Special Populations
The majority of the research, particularly the well-established RCTs, focuses on adult men with hypogonadism. The results apply only to the populations studied.
There is limited information available for specific comorbid groups (such as men with pre-existing, significant cardiovascular disease) within the high-quality, long-term RCT structure. As mentioned, evidence for adolescents with delayed puberty is limited to small clinical studies, and evidence for use in women with metastatic breast cancer is primarily historical. Data for certain groups remain insufficient to draw wide-ranging conclusions about patterns across all possible patient profiles.
Areas of Ongoing Research and Evidence Uncertainty
The evidence highlights what is known — and what is still uncertain — regarding the long-term use of this medicine.
The most significant research limitation often cited by authoritative bodies is the need for larger, definitive RCTs designed to track long-term clinical outcomes over periods greater than five to ten years. These are necessary to better characterize the findings for chronic conditions.
Research is ongoing to fully understand the long-term physiological impact of chronic testosterone replacement. Findings were mixed for some surrogate endpoints, such as those related to cardiovascular risk markers. The comparative evidence is lacking in certain areas, meaning it is not always clear how the long-term outcomes of injectable testosterone compare directly to other forms of testosterone replacement therapy.
